AI infrastructure and platform shifts accelerate cure timelines

Global active cure-related trials now total 21,140, with 73 new Wire signals and 33 new Cure research items emerging in the last 24h. The infrastructure and platform layer is tightening: AI data-center spending is projected to reach $32T by 2050, and a reported Nvidia–Hugging Face deal would consolidate control of a major model marketplace, while agentic AI adoption moves from code-generation pilots into broader software workflows. This matters because cure development is happening in a compute- and tooling-intensive phase-transition, where faster iteration can shorten the path from research to treatments—even as workers report productivity gains alongside job-loss anxiety. Across therapeutics, approvals and late-stage updates continue, including China’s NMPA approval for a subcutaneous lecanemab initiation approach in early Alzheimer’s and the completion of the last patient visit in NATiV3 Phase 3 for lanifibranor in MASH. The window is still open.